AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36349675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Handicap Inventory‐China scale in validation group (n = 564)
Number of subjects: 1129
Study 36349675 — intervention group
Group type: EXPERIMENTAL
Intervention: Content validity analysis in exploration group (n = 565)
Number of subjects: 1129
Study 36349675 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural validity analysis in validation group (n = 564)
Number of subjects: 1129
Study 32664149 — intervention group
Group type: EXPERIMENTAL
Intervention: Galgeun-tang (GGT)
Number of subjects: 160
Study 32664149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 33071012 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins-rich Queen Garnet Plum juice
Number of subjects: 16
Study 33071012 — intervention group
Group type: COMPARATOR
Intervention: Control (apricot juice)
Number of subjects: 16
Study 32927849 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom Active Breaks (CABs) program
Number of subjects: 115
Study 32927849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CABs)
Number of subjects: 115
Study 35761496 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous dual-task training (exercise and cognitive tasks), 24 sessions over 12 months, 60 mins per session
Number of subjects: 40
Study 35761496 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular outpatient visits)
Number of subjects: 40
Study 34245483 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA orifice with chicken wing type
Number of subjects: 200
Study 34245483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oval LAA orifice
Number of subjects: 200
Study 34245483 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA orifice size and shape
Number of subjects: 200
Study 34245483 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocardial surface roughness
Number of subjects: 200
Study 32201198 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 111
Study 32201198 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 111
Study 32201198 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 111
Study 32201198 — intervention group
Group type: COMPARATOR
Intervention: Preoperative N-terminal pro-brain natriuretic peptide
Number of subjects: 111
Study 35785080 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin combined with liraglutide
Number of subjects: 50
Study 35785080 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide alone (Control)
Number of subjects: 50
Study 34902081 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichoderma asperellum (quality and organic seed-treatment products)
Number of subjects: 3
Study 34902081 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 3
Study 34657873 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method (MDT)
Number of subjects: 60
Study 34657873 — intervention group
Group type: COMPARATOR
Intervention: Spiral Stabilization Method (SPS)
Number of subjects: 60
Study 34711601 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week school-based behaviour change intervention consisting of health education, family involvement, and school environment support.
Number of subjects: 64
Study 34711601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 64
Study 32929107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged bedrest
Number of subjects: 0
Study 32929107 — intervention group
Group type: COMPARATOR
Intervention: Resistive vibration exercise countermeasure during bedrest
Number of subjects: 0
Study 33947295 — intervention group
Group type: COMPARATOR
Intervention: Risankizumab 150 mg/mL administered via prefilled syringe (PFS)
Number of subjects: 0
Study 33947295 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg/mL administered via autoinjector (AI)
Number of subjects: 0
Study 33694234 — intervention group
Group type: EXPERIMENTAL
Intervention: S. indica-inoculated plants
Number of subjects: 4
Study 33694234 — intervention group
Group type: COMPARATOR
Intervention: Noninoculated control plants
Number of subjects: 4
Study 35955123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral smoking cessation treatment along with an App with active therapeutic components (SinHumo App)
Number of subjects: 0
Study 35955123 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioral treatment along with the use of a control App (without active components)
Number of subjects: 0
Study 33205991 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation to wear masks (supply of 50 surgical masks and instructions for proper use)
Number of subjects: 3030
Study 33205991 — intervention group
Group type: COMPARATOR
Intervention: No mask recommendation (control group)
Number of subjects: 3030
Study 33176870 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (rTMS) for 5 sessions within 2 weeks duration
Number of subjects: 76
Study 33176870 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 5 sessions within 2 weeks duration
Number of subjects: 76
Study 35170843 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal optimization technique (POT)
Number of subjects: 120
Study 35170843 — intervention group
Group type: COMPARATOR
Intervention: Kissing balloon technique (KBT)
Number of subjects: 120
Study 36263927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosnetupitant 235 mg infusion
Number of subjects: 158
Study 36263927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosnetupitant (17.6–353 mg) infusion
Number of subjects: 158
Study 36263927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosnetupitant
Number of subjects: 158
Study 36263927 — intervention group
Group type: COMPARATOR
Intervention: Oral NEPA
Number of subjects: 158
Study 32020287 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRF imaging using indocyanine green (ICG)
Number of subjects: 44
Study 32020287 — intervention group
Group type: COMPARATOR
Intervention: Traditional hepatectomy
Number of subjects: 44
Study 35046004 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age method
Number of subjects: 454
Study 35046004 — intervention group
Group type: COMPARATOR
Intervention: Nasal-tragus length (NTL) method
Number of subjects: 454
Study 32504593 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus LDFRT (0.5 Gy twice daily for 2 days)
Number of subjects: 108
Study 32504593 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy alone
Number of subjects: 108
Study 35755061 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-based dosing algorithm of bupivacaine
Number of subjects: 280
Study 35755061 — intervention group
Group type: COMPARATOR
Intervention: Constant dose of bupivacaine (Conventional group)
Number of subjects: 280
Study 32150229 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO Autism program (12 sessions, 2 hours each, over 6 months)
Number of subjects: 148
Study 32150229 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO Autism program
Number of subjects: 148
Study 35147294 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital teaching method
Number of subjects: 0
Study 35147294 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 0
Study 33452152 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 8056
Study 33452152 — intervention group
Group type: COMPARATOR
Intervention: Non-statin users (Control)
Number of subjects: 8056
Study 32442154 — intervention group
Group type: EXPERIMENTAL
Intervention: PD_manager system (mHealth platform including a wristband, sensor insoles, smartphone apps)
Number of subjects: 75
Study 32442154 — intervention group
Group type: EXPERIMENTAL
Intervention: PD_manager system (mHealth platform)
Number of subjects: 75
Study 35139047 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes of electrical stimulation
Number of subjects: 0
Study 35139047 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 minutes of electrical stimulation
Number of subjects: 0
Study 35139047 — intervention group
Group type: COMPARATOR
Intervention: 0 minutes of electrical stimulation (control)
Number of subjects: 0
Study 34655135 — intervention group
Group type: EXPERIMENTAL
Intervention: FITOPROT (mucoadhesive phytomedication containing curcuminoids and Bidens pilosa L.)
Number of subjects: 62
Study 34655135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 32443322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT) analysis of maxillary first premolars
Number of subjects: 648
Study 32443322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT) analysis of mandibular first premolars
Number of subjects: 648
Study 35184319 — intervention group
Group type: EXPERIMENTAL
Intervention: Chan-Chuang qigong program
Number of subjects: 80
Study 34119458 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP (My Viva Plan) web-based application used for 12 weeks
Number of subjects: 32
Study 34119458 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP (My Viva Plan) web-based application
Number of subjects: 32
Study 32090748 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI+GZA
Number of subjects: 56
Study 32090748 — intervention group
Group type: COMPARATOR
Intervention: SSRI+PBO
Number of subjects: 56
Study 34590205 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management survivorship intervention
Number of subjects: 147
Study 34590205 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study 32352644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin up to 10 mg once daily
Number of subjects: 100
Study 32352644 — intervention group
Group type: COMPARATOR
Intervention: Metformin up to 1,000 mg twice daily
Number of subjects: 100
Study 34251414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine (100 mg/m2 per day on days 4-10) and Daunorubicin (60 mg/m2 per day on days 4-6) followed by Cytarabine consolidation (2000 mg/m2 per day on days 4-8) with G3139 (7 mg/m2 per day on days 1-10 for induction or days 1-8 for consolidation)
Number of subjects: 506
Study 34251414 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine (100 mg/m2 per day on days 4-10) and Daunorubicin (60 mg/m2 per day on days 4-6) followed by Cytarabine consolidation (2000 mg/m2 per day on days 4-8) without G3139
Number of subjects: 506
Study 34251414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine (100 mg/m2 per day on days 4-10) and Daunorubicin (60 mg/m2 per day on days 4-6) followed by Cytarabine consolidation (2000 mg/m2 per day on days 4-8) with G3139
Number of subjects: 506
Study 36964526 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Education (GE)
Number of subjects: 370
Study 36964526 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-Centered Support (PCS)
Number of subjects: 370
Study 36964526 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Education (GE) and Person-Centered Support (PCS)
Number of subjects: 370
Study 36964526 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 370
Study 33451612 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cardiotocography
Number of subjects: 28
Study 33451612 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiotocography (Control)
Number of subjects: 28
Study 35271530 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual transvaginal ultrasonography
Number of subjects: 56
Study 35271530 — intervention group
Group type: COMPARATOR
Intervention: In-clinic transvaginal ultrasonography
Number of subjects: 56
Study 34664868 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate group (400 mL carbohydrate drink 2 hours before surgery)
Number of subjects: 58
Study 34664868 — intervention group
Group type: COMPARATOR
Intervention: NPO group (fast from midnight)
Number of subjects: 58
Study 34664868 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate group
Number of subjects: 58
Study 34664868 — intervention group
Group type: COMPARATOR
Intervention: NPO group
Number of subjects: 58
Study 33412771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy (DS)
Number of subjects: 144
Study 33412771 — intervention group
Group type: COMPARATOR
Intervention: Skin Scraping (SS)
Number of subjects: 144
Study 35112455 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing the UACR criterion from 300 mg/g to 210 mg/g
Number of subjects: 848
Study 35112455 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible albuminuria and eGFR-based inclusion criteria
Number of subjects: 848
Study 34048910 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination rollout
Number of subjects: 0
Study 35739541 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS program
Number of subjects: 186
Study 35739541 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 186
Study 35746117 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy based on the NDT Bobath concept
Number of subjects: 60
Study 35746117 — intervention group
Group type: COMPARATOR
Intervention: Classic exercises
Number of subjects: 60
Study 33820541 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming blanket and infusion thermometer
Number of subjects: 75
Study 33820541 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming blanket and incubator
Number of subjects: 75
Study 33820541 — intervention group
Group type: COMPARATOR
Intervention: Control group (warming blanket only)
Number of subjects: 75
Study 36190389 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises with blood flow restriction
Number of subjects: 28
Study 36190389 — intervention group
Group type: COMPARATOR
Intervention: Exercises without blood flow restriction
Number of subjects: 28
Study 34169526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10 mg twice daily)
Number of subjects: 40
Study 33307911 — intervention group
Group type: EXPERIMENTAL
Intervention: PariPEP S®
Number of subjects: 18
Study 33307911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acapella DH®
Number of subjects: 18
Study 33307911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobika®
Number of subjects: 18
Study 33861741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin (directly observed treatment)
Number of subjects: 1184
Study 33861741 — intervention group
Group type: COMPARATOR
Intervention: Usual care (referral for topical treatment)
Number of subjects: 1184
Study 36462274 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid simulation-based training
Number of subjects: 72
Study 36462274 — intervention group
Group type: COMPARATOR
Intervention: Classical-based training
Number of subjects: 72
Study 34388395 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 μg twice daily for 14 days)
Number of subjects: 4700
Study 34388395 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4700
Study 32962674 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-IMRT (60.62 Gy equivalent dose in 2-Gy fractions)
Number of subjects: 164
Study 32962674 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-IMRT + concurrent chemotherapy (weekly paclitaxel and a platinum-based drug for 5-6 weeks)
Number of subjects: 164
Study 32962674 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-IMRT + concurrent chemotherapy
Number of subjects: 164
Study 32962674 — intervention group
Group type: COMPARATOR
Intervention: SIB-IMRT
Number of subjects: 164
Study 35917698 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-polluted Road exposure
Number of subjects: 35
Study 35917698 — intervention group
Group type: COMPARATOR
Intervention: Traffic-free Park exposure
Number of subjects: 35
Study 35917698 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP exposure
Number of subjects: 35
Study 35470974 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐TRE+DCR (10-hour eating window starting within 3 hours of waking) plus DCR (35% DCR)
Number of subjects: 81
Study 32841739 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal Micronucleus Cytome Assay (BMCyt)
Number of subjects: 804
Study 33190559 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH intervention
Number of subjects: 159
Study 33190559 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 159
Study 33077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting and behavioral interventions
Number of subjects: 64
Study 33077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting
Number of subjects: 64
Study 36220069 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour time-restricted eating (TRE)
Number of subjects: 0
Study 36220069 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 0
Study 36220069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TRE and LCD
Number of subjects: 0
Study 33279481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic heart disease (HFpEF patients with ischemia)
Number of subjects: 3445
Study 33279481 — intervention group
Group type: COMPARATOR
Intervention: Nonischemic heart disease (HFpEF patients without ischemia)
Number of subjects: 3445
Study 33279481 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 3445
Study 33279481 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 3445
Study 33279481 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 3445
Study 33279481 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (in ischemic HFpEF patients)
Number of subjects: 3445
Study 32819394 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based contraceptive delivery (condoms, pills, injection, implant) during the routine 40-day postpartum visit.
Number of subjects: 208
Study 32819394 — intervention group
Group type: COMPARATOR
Intervention: Control clusters received comprehensive contraceptive counseling as part of routine care.
Number of subjects: 208
Study 35796434 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment programs (including skills-based training and hands-on placements)
Number of subjects: 5
Study 33544337 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 136
Study 33544337 — intervention group
Group type: COMPARATOR
Intervention: Comparator EGFR TKI (gefitinib 250 mg once daily or erlotinib)
Number of subjects: 136
Study 33275096 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin alone
Number of subjects: 1858
Study 33275096 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin plus graduated compression stockings
Number of subjects: 1858
Study 36455143 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Number of subjects: 60
Study 34389772 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy (DHC)
Number of subjects: 95
Study 36368598 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Number of subjects: 76
Study 36368598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 33791991 — intervention group
Group type: EXPERIMENTAL
Intervention: Game Changers intervention
Number of subjects: 98
Study 32053630 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate NPK treatment (50 kg N + 10 kg P + 50 kg K /ha)
Number of subjects: 0
Study 32053630 — intervention group
Group type: EXPERIMENTAL
Intervention: High NPK treatment (100 kg N + 25 kg P + 100 kg K /ha)
Number of subjects: 0
Study 32053630 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium only treatment (50 kg K/ha)
Number of subjects: 0
Study 32053630 — intervention group
Group type: COMPARATOR
Intervention: Control (no fertiliser applied)
Number of subjects: 0
Study 32053630 — intervention group
Group type: EXPERIMENTAL
Intervention: NPK fertiliser application
Number of subjects: 0
Study 32053630 — intervention group
Group type: EXPERIMENTAL
Intervention: NPK fertiliser application with corrected soil nutrient deficiencies
Number of subjects: 0
Study 35776034 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin-containing supplement (200 mg daily for 4 weeks)
Number of subjects: 66
Study 35776034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 66
Study 35383823 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (16,800 IU vitamin D3 once a week for 1 year)
Number of subjects: 155
Study 35383823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 35383823 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (16,800 IU vitamin D3 once a week for 1 year) in subgroup with 25(OH)D concentrations of 15-25 nmol/L (n=31)
Number of subjects: 155
Study 35383823 — intervention group
Group type: COMPARATOR
Intervention: Placebo in subgroup with 25(OH)D concentrations of 15-25 nmol/L (n=31)
Number of subjects: 155
Study 32879147 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin (rhTM)
Number of subjects: 2865
Study 32879147 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2865
Study 34716636 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolinguistic Programming training group
Number of subjects: 180
Study 34716636 — intervention group
Group type: COMPARATOR
Intervention: Standard training group
Number of subjects: 180
Study 34716636 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 34956849 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education on TB-DM combined with clinical monitoring and medication adjustment
Number of subjects: 150
Study 34956849 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control arm)
Number of subjects: 150
Study 34956849 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education on TB-DM
Number of subjects: 150
Study 34166100 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Task Analysis (CTA) tool
Number of subjects: 18
Study 34166100 — intervention group
Group type: COMPARATOR
Intervention: Control group (equipment instruction manual)
Number of subjects: 18
Study 36442202 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Games Training (CCT)
Number of subjects: 107
Study 36442202 — intervention group
Group type: COMPARATOR
Intervention: Web-based crossword puzzles (Control)
Number of subjects: 107